Comparative Pharmacology
Head-to-head clinical analysis: CHLOROPTIC S O P versus SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROPTIC S O P versus SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH.
CHLOROPTIC S.O.P. vs SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate synthesis. Together, they provide sequential blockade of folate metabolism, leading to bactericidal activity.
Apply 0.5-inch ribbon into the conjunctival sac(s) 1-2 times daily, or more frequently as directed.
1 double-strength tablet (800 mg sulfamethoxazole/160 mg trimethoprim) orally every 12 hours for most infections; single-strength tablet (400 mg/80 mg) is used for prophylaxis: 1 tablet orally daily.
None Documented
None Documented
Terminal half-life approximately 4-6 hours; clinical context: dosing every 4-6 hours for ocular infections
Sulfamethoxazole: 10-12 hours (prolonged in renal impairment); Trimethoprim: 8-11 hours (prolonged in hepatic impairment).
Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%)
Sulfamethoxazole: primarily renal (70-90% as unchanged drug and acetylated metabolite); Trimethoprim: renal (50-60% unchanged, rest as metabolites); small biliary/fecal elimination (<5% each).
Category C
Category D/X
Antibiotic
Antibiotic